RHB Investment Research Reports

IHH Healthcare - Uneven Recovery Path; Maintain BUY

Publish date: Wed, 30 Nov 2022, 10:35 AM
0 1,903
An official blog in I3investor to publish research reports provided by RHB Research team.

All materials published here are prepared by RHB Investment Bank Bhd. For latest offers on RHB Invest trading products and news, please refer to: http://www.rhbinvest.com

RHB Investment Bank Bhd
Level 3A, Tower One, RHB Centre
Jalan Tun Razak
Kuala Lumpur

Tel : +(60) 3 9280 8888
Fax : +(60) 3 9200 2216
  • Maintain BUY and SOP-derived TP of MYR7.42, 24% upside with c.1% yield. 9M22 earnings were below expectations, mainly due to a decline in COVID-19-related revenues and weakening TRY. However, we continue to favour this stock, as we believe IHH Healthcare’s recovery remains on track given the resilient demand for healthcare.
  • Earnings below expectations due to weaker-than-expected EBITDA from IHH’s Malaysia, India, and Acibadem operations, which represent 69%, 71%, and 63% of our FY22 forecasts. Its 9M22 core earnings of MYR1,065m (-2.2% YoY) made up 72% and 65% of our and Street’s FY22 estimates.
  • Solid recovery for Malaysia. Operationally, revenue intensity dropped 16% YoY in 3Q22 – offset by the growth in inpatient admissions (+57% YoY) post reopening of borders – while bed occupancy improved significantly to 70% (3Q21: 48%, 2Q22: 61%). This led to a 24% growth in EBITDA. We continue to expect recovery in Malaysia to remain intact, supported by domestic electives and disciplined cost measures.
  • Singapore EBITDA dropped 14% YoY in 3Q22 despite a 32% increase in revenue intensity due to cost pressures from nursing shortages on salaries, which resulted in lower margins. Inpatient admissions also dropped 4% YoY as a result of nursing shortages, leading to constraints on bed capacity.
  • India’s performance was slightly weaker YoY. Despite increasing patient admissions (+6% YoY) and higher revenue intensity (+8% YoY), India’s EBITDA fell 1% in 3Q22 – likely due to increases in operational costs. However, the relatively huge scale in India should allow IHH to better manage the rising operational costs by ramping up productivity. We anticipate a growth in its domestic electives and recovery in medical travel in the coming quarters.
  • Acibadem still posted weaker earnings. Despite higher revenue intensity (+45% YoY) in 3Q22, the weakening TRY vs the MYR and lower inpatient admissions (-1% YoY) eroded EBITDA (-23% YoY). However, we remain optimistic on Acibadem’s earnings through IHH’s continuous efforts to expand its non-TRY contributions (46% in YTD22 vs 41% FY21).
  • We make no changes to our FY22F-24F earnings, recommendation, and TP, pending the analysts briefing on 30 Nov. This counter is still trading at an undemanding 13x FY23F EV/EBITDA (-1SD of its 5-year mean). We ascribe a 0% ESG premium/discount to our intrinsic value, as IHH’s ESG score is in line with the country median.
  • Key downside risks. Mandatory Takeover Offer or MTO overhang on Fortis, lower-than-expected patient volume/revenue intensity, and higher- than-expected operating costs.

Source: RHB Research - 30 Nov 2022

Related Stocks
Be the first to like this. Showing 0 of 0 comments

Post a Comment